FDA Grants Accelerated Approval to Zanubrutinib for Marginal Zone Lymphoma
Approval is based on the results from the BGB-3111-214 and BGB-3111-AU-003 studies
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Approval is based on the results from the BGB-3111-214 and BGB-3111-AU-003 studies
Development of novel model for prediction of distant relapse in patients with early breast cancer
Findings from a phase II open-label study in patients with localised solid tumours
Findings from a first-in-human, modular study with samuraciclib (CT7001)
The results from the DESTINY-Lung01 study
The results of the ELDERLY study
Results of the GETUG/AFU VESPER V05 study
Interim results from a phase II study with and ATR inhibitor ceralasertib
The results from a prospective, phase III clinical study of extended treatment with 5 years of letrozole compared to 2 to 3 years of letrozole
The results from the studies conducted in patients with human papillomavirus associated malignancies
Findings from a randomised, open-label, phase II study
FDA also approved the Oncomine Dx Target Test as a companion diagnostic device
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.